Apr 6, 2026
DALLAS, TEXAS – APRIL 6, 2026 Reapplix today announced it has been awarded a Technology Breakthrough designation with Premier Inc. for its 3C Patch® Wound Management System. Premier offers Breakthrough Technology designations to innovations that offer a major...
May 22, 2023
Contract awarded for products that bring improvement to health care industry (Southlake, TX) –Reapplix announced its 3C Patch® Wound Management System has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven healthcare...
Oct 6, 2021
3C Patch® is a first-in-class advanced biologic autologous cell therapy targeting hard-to-heal diabetic foot ulcers (Birkerod, Denmark) – Reapplix, a privately-held, regenerative medicine company today announces, that coding details and reimbursement level have been...
May 3, 2021
Kira Rupprecht brings substantial U.S. commercialization and product launch experience 3 May 2021 – (Birkerod, Denmark and Los Angeles, Calif.) – The Board of Directors of Reapplix, a company specializing in the biological treatment and management of diabetic foot...
Apr 21, 2021
Commercialization of this unique, breakthrough treatment for diabetic foot ulcers to be accelerated in the United States (Birkerod, Denmark) – Reapplix announces that a final National Coverage Determination (NCD) from the Centers for Medicare and Medicaid...
Oct 20, 2020
Reapplix is today very pleased to be able to announce that Richard Twomey has been appointed to the Board of Directors. Mr. Twomey is a highly respected healthcare executive who for the past six years, to September 2020, has held the position of CEO and President of...
